Cargando…

Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy

OBJECTIVE: We evaluate the predictive significance of the Advanced Lung Cancer Inflammation Index (ALI) in patients with advanced hepatocellular carcinoma (HCC) following therapy with immune checkpoint drugs. METHODS: In 2018-2020, 98 patients with advanced hepatocellular carcinoma who were treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qian, Ma, Fei, Wang, Ju feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043333/ https://www.ncbi.nlm.nih.gov/pubmed/36998452 http://dx.doi.org/10.3389/fonc.2023.997314

Ejemplares similares

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

An inflammation-related gene landscape predicts prognosis and response to immunotherapy in virus-associated hepatocellular carcinoma
por: Gao, Ying-jie, et al.
Publicado: (2023)

Advanced Lung Cancer Inflammation Index Predicts Survival Outcomes of Patients With Oral Cavity Cancer Following Curative Surgery
por: Tsai, Yao-Te, et al.
Publicado: (2021)

The value of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the prognosis of patients with hepatocellular carcinoma treated with camrelizumab: a retrospective cohort study
por: Li, Qian, et al.
Publicado: (2022)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Systemic Inflammation Response Index Is a Predictor of Poor Survival in Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matching Study
por: Feng, Yuhua, et al.
Publicado: (2020)

Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

Sarcopenia and Systemic Inflammation Response Index Predict Response to Systemic Therapy for Hepatocellular Carcinoma and Are Associated With Immune Cells
por: Zhao, Man, et al.
Publicado: (2022)

The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization
por: Chien, Tzu-Ping, et al.
Publicado: (2022)

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
por: Son, Christine, et al.
Publicado: (2023)

Preoperative Prognostic Nutritional Index and Neutrophil-to-Lymphocyte Ratio Predict Survival Outcomes of Patients With Hepatocellular Carcinoma After Curative Resection
por: Qu, Zhen, et al.
Publicado: (2022)

Nomogram Based on Systemic Immune Inflammation Index and Prognostic Nutrition Index Predicts Recurrence of Hepatocellular Carcinoma After Surgery
por: Yang, Junsheng, et al.
Publicado: (2020)

Association of systemic inflammation index with survival in patients with advanced perihilar cholangiocarcinoma treated with interventional therapy
por: Li, Jinyu, et al.
Publicado: (2022)

ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma
por: Zhang, Yu, et al.
Publicado: (2022)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

The prognostic significance of inflammation-immunity-nutrition score on postoperative survival and recurrence in hepatocellular carcinoma patients
por: Liang, Yuxin, et al.
Publicado: (2022)

Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
por: Zhong, Cheng, et al.
Publicado: (2021)

Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib
por: Liu, Bo, et al.
Publicado: (2022)

Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After
por: Woody, Susan, et al.
Publicado: (2022)

CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy
por: Lin, Qian, et al.
Publicado: (2022)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib
por: Rana, Nitesh, et al.
Publicado: (2013)

Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy
por: Fan, Ruiyun, et al.
Publicado: (2023)

Nomograms for Predicting Hepatocellular Carcinoma Recurrence and Overall Postoperative Patient Survival
por: Ma, Lidi, et al.
Publicado: (2022)

A Nomogram to Predict Survival in Patients With Locoregional Recurrent Nasopharyngeal Carcinoma Receiving Comprehensive Treatment
por: Wei, Ying-Hong, et al.
Publicado: (2022)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Huang, Xiaozhun, et al.
Publicado: (2021)

Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
por: Qin, Jian, et al.
Publicado: (2022)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma
por: Yang, Dashuai, et al.
Publicado: (2022)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma
por: Zhu, Jun, et al.
Publicado: (2022)

Prognostic implications of systemic immune-inflammation index in patients with bone metastases from hepatocellular carcinoma treated with radiotherapy
por: Chen, Jingyao, et al.
Publicado: (2023)

Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Chiang, Chi-Leung, et al.
Publicado: (2021)

Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
por: Hua, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rcrrabe53tfcjglm69e5jn1vhv